Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
Who is this study for? Adult patients with COVID-19 Infection
Status: Completed
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
Locations
United States
Connecticut
Bridgeport Hospital
Bridgeport
Greenwich Hospital
Greenwich
Yale New Haven Hosptial System
New Haven
Lawrence & Memorial Hospital
New London
Time Frame
Start Date: 2020-10-30
Completion Date: 2022-03-30
Participants
Target number of participants: 250
Treatments
Experimental: Standard of Care (SOC) and Colchicine+Rosuvastatin
Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
No_intervention: Standard of care (SOC)
Patients will undergo standard of care treatment during hospitalization determined by the primary care team during hospitalization
Related Therapeutic Areas
Sponsors
Leads: Yale University